ArticleBiomacromolecules2022
Hyaluronic Acid-PEG-Based Diels-Alder
Article in Biomacromolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 53 citations in OpenAlex.
- A Comprehensive Review on Engineering Release at the Molecular Level: Role of Functional Groups in Polysaccharide-Based Drug Delivery.Materials (Basel, Switzerland) · 2026Review
- Clinical translation of injectable hydrogels: from bioactive polymers to long-acting drug delivery systems.Drug delivery and translational research · 2026Review
- Diels-Alder Click Chemistry as a Dynamic-Covalent Crosslinking Method in Spheroid-Encapsulating Hydrogels for Cartilage Engineering.Advanced healthcare materials · 2026Article
- The Gastrointestinal Tract: A Unique Battlefield for Bioengineering Delivery Platforms.Bioengineering (Basel, Switzerland) · 2025Review
- In-Depth Investigation of Electrostatic Interaction-Based Hydrogel Shrinking for Volumetric Printing and Tissue Engineering Applications.Biomacromolecules · 2025Article
- Fast Wound Healing with a New Functional Hyaluronic Acid Dual Network Hydrogel.Gels (Basel, Switzerland) · 2025Article
- Diverse reactivity of maleimides in polymer science and beyond.Polymer international · 2025Article
- Development of Amniotic Epithelial Stem Cells Secretome-LoadedACS applied materials & interfaces · 2025Article
- Injectable Hydrogels for Programmable Nanoparticle Release.Advanced functional materials · 2025Article
- Hybrid NIR-responsive liposome/hydrogel platform mediating chemo-photothermal therapy of retinoblastoma enhanced by quercetin as an adjuvant.Theranostics · 2025Article
- Applications of Diels-Alder Chemistry in Biomaterials and Drug Delivery.Macromolecular bioscience · 2024Review
- Injectable Dendrimer Hydrogel Delivers Melphalan in Both Conjugated and Free Forms for Retinoblastoma.Biomacromolecules · 2024Article
- Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes as Nanomedicine for Peripheral Nerve Injury.International journal of molecular sciences · 2024Review
- Metal-Free Click-Chemistry: A Powerful Tool for Fabricating Hydrogels for Biomedical Applications.Bioconjugate chemistry · 2024Review
- Poly(glutamic acid)-Based Viscosity Reducers for Concentrated Formulations of a Monoclonal IgG Antibody.Molecular pharmaceutics · 2024Article
- The mechanics of the retina: Müller glia role on retinal extracellular matrix and modelling.Frontiers in medicine · 2024Review
- Hydrogels in Ophthalmology: Novel Strategies for Overcoming Therapeutic Challenges.Materials (Basel, Switzerland) · 2023Review
- Innovative Strategies for Drug Delivery to the Ocular Posterior Segment.Pharmaceutics · 2023Review
- Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases.Pharmaceutics · 2023Review
- Recent Advances in Hydrogels via Diels-Alder Crosslinking: Design and Applications.Gels (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinal diseases are the leading cause of visual impairment worldwide. The effectiveness of antibodies for the treatment of retinal diseases has been demonstrated. Despite the clinical success, achieving sufficiently high concentrations of these protein therapeutics at the target tissue for an extended period is challenging. Patients suffering from macular degeneration often receive injections once per month. Therefore, there is a growing need for suitable systems that can help reduce the number of injections and adverse effects while improving patient complacency. This study systematically characterized degradable "
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.